Summary:
Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY): A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Underlying HeFH and/or Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled by Their Lipid-Modifying Therapies
Qualified Participants Must:
• Be 18 years and older
• Have elevated bad cholestrol
• Be taking cholestrol medication
• Have Cardiovasular disease
• Be avaliable for out patient visits